UK markets closed
  • FTSE 100

    5,577.27
    -4.48 (-0.08%)
     
  • FTSE 250

    17,214.38
    +36.70 (+0.21%)
     
  • AIM

    948.60
    -0.70 (-0.07%)
     
  • GBP/EUR

    1.1115
    +0.0051 (+0.46%)
     
  • GBP/USD

    1.2951
    +0.0028 (+0.22%)
     
  • BTC-GBP

    10,480.01
    +26.37 (+0.25%)
     
  • CMC Crypto 200

    265.42
    +1.78 (+0.68%)
     
  • S&P 500

    3,269.96
    -40.15 (-1.21%)
     
  • DOW

    26,501.60
    -157.51 (-0.59%)
     
  • CRUDE OIL

    35.72
    -0.45 (-1.24%)
     
  • GOLD FUTURES

    1,878.80
    +10.80 (+0.58%)
     
  • NIKKEI 225

    22,977.13
    -354.81 (-1.52%)
     
  • HANG SENG

    24,107.42
    -479.18 (-1.95%)
     
  • DAX

    11,556.48
    -41.59 (-0.36%)
     
  • CAC 40

    4,594.24
    +24.57 (+0.54%)
     

Summit Announces Agreement For a Fundraising of approximately $50 Million

Summit Therapeutics plc
·4-min read

Summit Therapeutics Inc.

(“Summit” or the “Company”)

Summit Announces Agreement For a Fundraising of approximately $50 Million

Cambridge, MA, October 2, 2020 – Summit (NASDAQ: SMMT) today announces that it has entered into a binding agreement with the Company’s Chief Executive Officer and Executive Chairman, Robert W. Duggan, for a fundraising of approximately $50 million (the “Fundraising”) through the issuance and sale in a private placement of shares of common stock to Mr. Duggan. The transaction provides Summit the ability to place up to 14,970,060 new shares of common stock with Mr. Duggan in exchange for up to $50 million in new investment. The aggregate purchase price will reflect a price of $3.34 per share of common stock. The price per share of the common stock sold in the Fundraising represents the Nasdaq closing price per share immediately preceding the entry into the binding agreement for the Fundraising.

The purchase agreement also affords Summit the flexibility to place fewer than the maximum shares of common stock with Mr. Duggan, in the Company’s discretion, provided that no less than 9,730,539 shares of common stock shall be sold to Mr. Duggan in the offering. Prior to the closing of the Fundraising, which Summit expects to occur in approximately two weeks’ time, the Company intends to engage with third parties who may have an interest in making an investment in the Company on similar terms as those agreed with Mr. Duggan.

Summit believes that the net proceeds of the Fundraising will extend its cash runway to the third quarter of 2021. The Company expects to use these funds to support the following activities:

  • Ridinilazole: Continued patient enrolment into the Ri-CoDIFy Phase 3 clinical trial program of ridinilazole for the treatment of Clostridium difficile infection.

  • Ridinilazole: Preparatory activities to support the commercial launch of ridinilazole, if approved.

  • Development of early-stage research projects using the Company’s Discuva Platform.

  • General corporate purposes.

The securities issued to Mr. Duggan at the closing and any securities issued to third parties on similar terms on or around such date will not be registered under the Securities and Exchange Act of 1933, as amended, and may not be offered or sold absent registration or an applicable exemption from registration requirements.

Contact
Summit Press Office
investors@summitplc.com



Michael Donaldson, Chief Financial Officer
mike.donaldson@summitplc.com




Summit Forward-looking Statements

Any statements in this press release about the Company’s future expectations, plans and prospects, including but not limited to, statements about the timing for the closing of the Fundraising, clinical and preclinical development of the Company’s product candidates, the therapeutic potential of the Company’s product candidates, the potential commercialization of the Company’s product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, global public health crises, including the coronavirus COVID-19 outbreak, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the “Risk Factors” section of filings that the Company makes with the Securities and Exchange Commission, including the Company’s Current Report on Form 8-K filed on September 29, 2020 with certain disclosures regarding the three and six months ended June 30, 2020. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.